Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
COPD, Chronic Bronchitis, Emphysema
Interventions
pneumatic vest, placebo pneumatic vest
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan
Completed Not applicable Interventional Accepts healthy volunteers

Inhaler Trainer Efficacy Study

NCT06461403
Conditions
Asthma, Copd, Acute Exacerbation of COPD
Interventions
Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
Device · Other
Lead sponsor
Koronis Biomedical Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
COPD Exacerbation
Interventions
Intervention
Behavioral
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
55 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Enrolling by invitation No phase listed Observational

Study on Home Obstructive Respiratory Exacerbations

NCT06544928
Conditions
COPD Exacerbation, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, COPD Exacerbation Acute, COPD
Interventions
RESP™ Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Pneumocystis in COPD (the TOPIC Study)

NCT05418777
Conditions
COPD Exacerbation Acute
Interventions
Trimethoprim Sulfamethoxazole, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
40 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
COPD Acute Exacerbation
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more
Completed Not applicable Interventional Results available

Digihaler in Chronic Obstructive Pulmonary Disease (COPD)

NCT05241288
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Albuterol eMDPI DS
Combination Product
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Florence, Alabama • Fountain Valley, California + 44 more
Completed No phase listed Observational Accepts healthy volunteers

Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations

NCT00774176
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
1,066 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Copd
Interventions
Interprofessional Education (IPE), Usual care
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
23 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Springfield, Massachusetts
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Cohort 1: Dupilumab, Cohort 2: usual care only
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Indianapolis, Indiana • Durham, North Carolina • North Richland Hills, Texas
Conditions
Chronic Obstructive Pulmonary Disease, COPD Exacerbation, Airflow Obstruction
Interventions
High Flow Nasal Cannula
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Efficacy and Safety of AQX-1125 in Unstable COPD

NCT01954628
Conditions
COPD
Interventions
AQX-1125, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Chronic Obstructive Pulmonary Disease, Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
Bundle tool
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
40 Years to 99 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more
Completed Phase 2 Interventional Results available

Tezepelumab COPD Exacerbation Study

NCT04039113
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
27
States / cities
Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more
Conditions
Copd, COPD Exacerbation, COPD Bronchitis, Emphysema or COPD, Chronic Lung Disease, Pulmonary Fibrosis, Interstitial Lung Disease, Bronchiectasis, Chronic Asthma, Chronic Asthmatic Bronchitis
Interventions
Onsite Maintenance Exercise Training, Telehealth Maintenance Exercise
Combination Product
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
COPD, Emphysema or COPD, COPD Exacerbation, COPD Exacerbation Acute, Respiratory Failure, Ventilatory Failure
Interventions
Methylprednisolone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 89 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion, Acute Rejection of Lung Transplant (Disorder), Airway Obstruction, Rib Fractures, Acute Copd Exacerbation, Asthma COPD, Pulmonary Embolism, Hemothorax, Pneumothorax, Mesothelioma, Diaphragmatic Paralysis
Interventions
Portable Dynamic Digital Radiography (DDR)
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lung Diseases, Bronchitis, Chronic
Interventions
Avelox (Moxifloxacin, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more
Conditions
Chronic Obstructive Airways Disease Exacerbated, Chronic Obstructive Airway Disease
Interventions
Digital Inhaler Attachment
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
COPD Exacerbation, Care Transitions
Interventions
Virtual at Home Medication Reconciliation Visit(s), Virtual At Home Medication Education Visit(s), COPD advanced practice nurse Inpatient Consult, Inpatient Medication Reconciliation, Post-discharge nurse 48 hour phone follow-up call, Post-discharge follow-up advanced practice nurse outpatient visit
Other · Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois